ionispharma.com (IONS) Enterprise Value to EBITDA Ratio
The technological foundation of Ionis Pharmaceuticals (IONS) is protected by a robust patent portfolio that creates significant barriers to entry for competitors. Ionis Pharmaceuticals seeks total dominance in RNA therapeutics, commercializing innovations independently to maximize profits. A specialization in rare pathologies guarantees a steady cash flow from the lifelong treatment of patients. Changes in the EV/EBITDA multiple help filter out market noise, while 0.00 serves as the final level marker.
Metric breakdowns and analytics for ionispharma.com (IONS)
- market price and analyst price targets:
- market capitalization details:
- business book valuation details:
- debt and solvency information:
- business earnings and investment ratios data:
IONS - Net Income|Projected Future Earnings Ionis Pharmaceuticals|IONS - Market Cap to Earnings|Projected Price to Earnings Ionis Pharmaceuticals|IONS - PEG Multiple|Enterprise Value to EBITDA Ratio Isis Pharmaceuticals|IONS - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Ionis|IONS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth ionispharma.com|IONS - Net earnings per share growth this year|Earnings growth forecast for next year Ionis Pharmaceuticals
Summary company analysis:IONS (Ionis Pharma)
This indicator assesses the business value relative to its operating profit, neutralizing the impact of debt load and tax regimes. It determines how many years Ionis Pharmaceuticals (IONS) would require to recoup all assets through current cash flow. For Ionis Pharmaceuticals (IONS), this parameter is critical during the transition to a direct sales model and large-scale R&D investments. The EV/EBITDA trend over the time interval reflects the market's revaluation of the efficiency of this strategic transformation.
Competitors of Ionis Pharmaceuticals (IONS)
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Total Company Value to Operating Income Before Depreciation Ratio Qiagen Corp (QGEN)|RGEN: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RNA (aviditybiosciences.com)|CRISPR Therapeutics (CRSP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio WGS (GeneDx Holdings)|RARE (Ultragenyx Pharma) - EV/EBITDA Multiple|BEAM: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SRPT|EV/EBITDA Multiple twistbioscience.com (TWST)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 10x Genomics TXG|Business Value to Operating Income Before Depreciation NTLA|STOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BioLife (BLFS) - Enterprise Value to EBITDA Ratio|WVE: EV/EBITDA Multiple|mazetx.com (MAZE) - EV/EBITDA Multiple|SION (Sionna Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Prime Medicine Inc (PRME)|EV/EBITDA Multiple TSHA|QURE - Company Value to EBITDA|MeiraGTx Holdings plc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple regenxbio.com RGNX|SLDB: Enterprise Value to EBITDA Ratio|Ocugen Inc - Enterprise Value to Operating Income Before Depreciation Ratio|PACB: EV/EBITDA Multiple|BNTC - Total Company Value to Operating Income Before Depreciation Ratio|DSGN (Design Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio rocketpharma.com (RCKT)|EV/EBITDA Multiple FDMT|EV/EBITDA Multiple lexeotx.com (LXEO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|Editas Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR Therapeutics N.V. PRQR|CDXS: EV/EBITDA Multiple|SGMO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Biotechnology, Inc.|Company Value to EBITDA Metagenomi Therapeutics MGX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|generationbio.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boundless Bio BOLD|Total Company Value to Operating Income Before Depreciation Ratio Exicure Inc. (XCUR)|Celsion Corporation - EV/EBITDA Multiple|PHIO (Phio Pharmaceuticals) - Enterprise Value to Operating Income Before Depreciation|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Sciences Inc|EV/EBITDA Multiple BLUE|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|singulargenomics.com (OMIC) - Company Value to EBITDA|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SYRS (Syros Pharmaceuticals Inc.) - Enterprise Value to Operating Income Before Depreciation|TBIO: EV/EBITDA Multiple|TCON - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
